Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar with pemetrexed plus platinum in first-line EGFR wild-type / ALK-negative advanced lung adenocarcinoma
ChiCTR-OPC-16008556Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jun 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of endostar, pemetrexed, cisplatin and carboplatin in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: progression-free survival. Started Jun 2016; status: recruiting.
02
Drugs
endostarpemetrexedcisplatincarboplatin
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR-OPC-16008556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16008556.